Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Premium Phosphosite-Specific 7TM Antibodies

Phosphorylation of intracellular serine and threonine residues is the most important post translational modification of G protein-coupled receptors (GPCRs) also called heptahelical or seven transmembrane receptors (7TMR). After agonist exposure, these receptors acquire an active conformation, which is recognized by a family of highly specialized GPCR kinases (GRKs). Agonist-driven phosphorylation by GRKs regulates acute receptor desensitization, arrestin recruitment, internalization, post-activation signaling, long-term tolerance and drug addiction. Phosphosite-specific 7TM antibodies are designed to specifically detect agonist-activated GPCRs. In fact, recent work shows that ligand profiling using phosphosite-specific 7TM antibodies provides valuble information on ligand bias beyond that obtained with conventional ß-arrestin recruitment assays. Phosphosite-specific 7TM antibodies are novel tools for GPCR research that can be used to:

  • profile agonist properties of novel GPCR ligands
  • decipher the phosphorylation barcode of GPCRs
  • determine the spatial and temporal dynamics of receptor phosphorylation
  • identify relevant kinases and phosphatases for GPCR phosphorylation and dephosphoryation

Lifecycle3

Schematic representation of the G protein-coupled receptor phosphorylation / dephosphorylation cycle. GRK, G protein-coupled receptor kinase; PKC, protein kinase C; cPP1, catalytic subunit of protein phosphatase 1; R*, activated GPCR; CCP, clathrin-coated pit. 

Close filters
21 From 42
No results were found for the filter!
NEW
Agonist-induced Serine355 phosphorylation of the β2-Adrenoceptor
pS355-β2 (phospho-β2-Adrenoceptor Antibody)
Serine355 (S355) is a major phosphorylation site of the β2 adrenoceptor. The pS355-β2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. S355 phosphorylation is primarily...
CHF400.00 *
Details
NEW
Agonist-induced Serine356 phosphorylation of the β2-Adrenoceptor
pS356-β2 (phospho-β2-Adrenoceptor Antibody)
Serine356 (S356) is a major phosphorylation site of the β2 adrenoceptor. The pS356-β2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. S356 phosphorylation is primarily...
CHF400.00 *
Details
NEW
Agonist-induced Threonine360 phosphorylation of the β2-Adrenoceptor
pT360-β2 (phospho-β2-Adrenoceptor Antibody)
Threonine360 (T360) is a major phosphorylation site of the β2 adrenoceptor. The pT360-β2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. T360 phosphorylation is primarily...
CHF400.00 *
Details
NEW
Agonist-induced Serine351/Serine353 phosphorylation of the Sphingosine 1-Phosphate Receptor 1
pS351/pS353-S1P1 (phospho-Sphingosine...
Serine351/Serine353 (S351/S353) is major phosphorylation site of the Sphingosine 1-Phosphate Receptor 1 (S1P1). The pS351/pS353-S1P1 antibody detects phosphorylation in response to agonists. S351/S353 phosphorylation is likely to be...
CHF400.00 *
Details
NEW
Agonist-induced Serine366/Serine367 phosphorylation of the Sphingosine 1-Phosphate Receptor 5
pS366/pS367-S1P5 (phospho-Sphingosine...
Serine366/Ser367 (S366/S367) is major phosphorylation site of the Sphingosine 1-Phosphate Receptor 5 (S1P5). The pS366/pS367-S1P5 antibody detects phosphorylation in response to agonists. S366/S367 phosphorylation is likely to be...
CHF400.00 *
Details
NEW
Agonist-induced Serine353/Serine355 phosphorylation of the Sphingosine 1-Phosphate Receptor 1
pS353/pS355-S1P1 (phospho-Sphingosine...
Serine353/Serine355 (S353/S355) is major phosphorylation site of the Sphingosine 1-Phosphate Receptor 1 (S1P1). The pS353/pS355-S1P1 antibody detects phosphorylation in response to agonists. S353/S355 phosphorylation is likely to be...
CHF400.00 *
Details
NEW
Agonist-induced Serine358/Serine359 phosphorylation of the Sphingosine 1-Phosphate Receptor 1
pS358/pS359-S1P1 (phospho-Sphingosine...
Serine358/Serine359 (S358/S359) is major phosphorylation site of the Sphingosine 1-Phosphate Receptor 1 (S1P1). The pS358/pS359-S1P1 antibody detects phosphorylation in response to agonists. S358/S359 phosphorylation is likely to be...
CHF400.00 *
Details
NEW
Agonist-induced Serine383/Serine384 phosphorylation of the Proteinase-Activated Receptor 2
pS383/pS384-PAR2 (phospho-Proteinase-Activated...
Serine383/Serine384 (S383/S384) is major phosphorylation site of the Proteinase-Activated Receptor 2 (PAR2). The pS383/pS384-PAR2 antibody detects phosphorylation in response to agonists. S383/S384 phosphorylation is likely to be...
CHF400.00 *
Details
NEW
Agonist-induced Serine326/Threonine327 phosphorylation of the Complement C5a Receptor 2.
pS326/pT327-C5a2 (phospho-Complement C5a...
Serine326/Threonine327 (S326/T327) is major phosphorylation site of the Complement Peptide Receptor 2 (C5a2). The pS326/pT327-C5a2 antibody detects phosphorylation in response to agonists. S326/S327 phosphorylation is likely to be...
CHF400.00 *
Details
NEW
Agonist-induced Serine332/Serine334 phosphorylation of the Complement C5a Receptor 1.
pS332/pS334-C5a1 (phospho-Complement C5a...
Serine332/serine334 (S332/S334) is a major phosphorylation site of the C5a1 receptor. The pS332/pS334-C5a1 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. S332/S334...
CHF400.00 *
Details
NEW
Agonist-induced Threonine324/Serine327 phosphorylation of the Complement C5a Receptor 1.
pT324/pS327-C5a1 (phospho-Complement C5a...
Threonine324/serine327 (T324/S327) is a major phosphorylation site of the C5a1 receptor. The pT324/pS327-C5a1 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. T324/S327...
CHF400.00 *
Details
NEW
Agonist-induced Serine320/Serine321 phosphorylation of the CXC Chemokine Receptor 6
pS320/pS321-CXCR6 (phospho-CXC Chemokine...
Serine320/Serine321 (S320/S321) is a major phosphorylation site of the CXCR6 receptor. The pS320/pS321-CXCR6 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. S320/S321...
CHF400.00 *
Details
NEW
Agonist-induced Serine325/Threonine327 phosphorylation of the CXC Chemokine Receptor 6
pS325/pT327-CXCR6 (phospho-CXC Chemokine...
Serine325/Threonine327 (S325/T327) is a major phosphorylation site of the CXCR6 receptor. The pS325/pT327-CXCR6 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. S325/T327...
CHF400.00 *
Details
NEW
Agonist-induced Serine329/Serine331 phosphorylation of the CXC Chemokine Receptor 6
pS329/pS331-CXCR6 (phospho-CXC Chemokine...
Serine329/Serine331 (S329/S331) is a major phosphorylation site of the CXCR6 receptor. The pS329/pS331-CXCR6 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. S329/S331...
CHF400.00 *
Details
NEW
Agonist-induced Serine338/Threonine342 phosphorylation of the Atypical Chemokine Receptor 4
pS338/pT342-ACKR4 (phospho-Atypical Chemokine...
Serine338/Threonine342 (S338/T342) is major phosphorylation site of the Atypical Chemokine Receptor 4 (ACKR4). The pS338/pT342-ACKR4 antibody detects phosphorylation in response to agonists. S338/ST42 phosphorylation is likely to be...
CHF400.00 *
Details
NEW
Immunohistochemical identification of Neurotensin Receptor 1 in Septum
NTS1 (GP-IHC-grade), Neurotensin Receptor 1...
The NTS1 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Neurotensin Receptor 1. It can be used to detect total NTS1 receptors in Western blots independent of phosphorylation. The NTS1 antibody...
CHF400.00 *
Details
21 From 42

For further reading refer to:

Kliewer A, Reinscheid RK, Schulz S. Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation. Trends Pharmacol Sci. 2017 Jul;38(7):621-636. doi:10.1016/j.tips.2017.04.002. Epub 2017 May 4. Review. PubMed PMID: 28478994.

Miess E, Gondin AB, Yousuf A, Steinborn R, Mösslein N, Yang Y, Göldner M, Ruland JG, Bünemann M, Krasel C, Christie MJ, Halls ML, Schulz S, Canals M. Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Sci Signal. 2018 Jul 17;11(539). pii: eaas9609. doi: 10.1126/scisignal.aas9609. PubMed PMID: 30018083.

Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, Williams JT, Christie MJ, Schulz S. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019 Jan 21;10(1):367. doi: 10.1038/s41467-018-08162-1. PubMed PMID: 30664663; PubMed Central PMCID: PMC6341117.

Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S. Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Sci Signal. 2019 Mar 26;12(574). pii: eaau8072. doi: 10.1126/scisignal.aau8072. PubMed PMID: 30914485; PubMed Central PMCID: PMC6934085.

Saaber F, Schütz D, Miess E, Abe P, Desikan S, Ashok Kumar P, Balk S, Huang K, Beaulieu JM, Schulz S, Stumm R. ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin. Cell Rep. 2019 Feb 5;26(6):1473-1488.e9. doi: 10.1016/j.celrep.2019.01.049. PubMed PMID: 30726732.

Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry. 2014 Nov 15;76(10):767-74. doi: 10.1016/j.biopsych.2014.01.021. Epub 2014 Feb 3. PubMed PMID: 24629717; PubMed Central PMCID: PMC4119866.

For further reading refer to: Kliewer A, Reinscheid RK, Schulz S. Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation. Trends Pharmacol Sci. 2017 Jul;38(7):621-636.... read more »
Close window
Premium Phosphosite-Specific 7TM Antibodies

For further reading refer to:

Kliewer A, Reinscheid RK, Schulz S. Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation. Trends Pharmacol Sci. 2017 Jul;38(7):621-636. doi:10.1016/j.tips.2017.04.002. Epub 2017 May 4. Review. PubMed PMID: 28478994.

Miess E, Gondin AB, Yousuf A, Steinborn R, Mösslein N, Yang Y, Göldner M, Ruland JG, Bünemann M, Krasel C, Christie MJ, Halls ML, Schulz S, Canals M. Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Sci Signal. 2018 Jul 17;11(539). pii: eaas9609. doi: 10.1126/scisignal.aas9609. PubMed PMID: 30018083.

Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, Williams JT, Christie MJ, Schulz S. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019 Jan 21;10(1):367. doi: 10.1038/s41467-018-08162-1. PubMed PMID: 30664663; PubMed Central PMCID: PMC6341117.

Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S. Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Sci Signal. 2019 Mar 26;12(574). pii: eaau8072. doi: 10.1126/scisignal.aau8072. PubMed PMID: 30914485; PubMed Central PMCID: PMC6934085.

Saaber F, Schütz D, Miess E, Abe P, Desikan S, Ashok Kumar P, Balk S, Huang K, Beaulieu JM, Schulz S, Stumm R. ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin. Cell Rep. 2019 Feb 5;26(6):1473-1488.e9. doi: 10.1016/j.celrep.2019.01.049. PubMed PMID: 30726732.

Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry. 2014 Nov 15;76(10):767-74. doi: 10.1016/j.biopsych.2014.01.021. Epub 2014 Feb 3. PubMed PMID: 24629717; PubMed Central PMCID: PMC4119866.

Recently viewed